<DOC>
	<DOC>NCT02905253</DOC>
	<brief_summary>The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults</brief_summary>
	<brief_title>A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects</brief_title>
	<detailed_description>The study is designed in three parts, A, B and C Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose Part C: single-center, open-label, single dose in CYP2C9 poor metabolizers</detailed_description>
	<criteria>Signed informed consent in the local language prior to any studymandated procedure Healthy male subjects for Part A, healthy male and female subjects for Part B and Part C aged between 18 and 55 years (inclusive) at screening No clinically significant findings on physical examination at screening Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening CYP2C9 poor metabolizers (Part C) History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed) Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions Treatment or substances known to induce CYP enzyme drug metabolism within 30 days prior to first study treatment administration Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol Known allergic reactions or hypersensitivity to the study treatment or drugs of the same class, or any of their excipients For Part A and Part B, CYP2C9 poor metabolizers enrolled in a cohort to be dosed with single or multiple dose of 500 mg or higher of ACT774312 (confirmed by genotyping before enrollment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>